Medications: As outlined in the study by Kibirige, D
These include: dual-agonist incretin peptides triple-agonist metabolic peptides amylin-based hormone combinations next-generation incretin mimetics Together, these compounds represent the future direction of metabolic peptide research
By merging these analogs, researchers aim to explore how their complementary mechanisms may provide a broader perspective on growth hormone modulation
22 Continued research is required to evaluate the cardiovascular effects of resmetirom in patients with MASH, who face a higher risk of death from cardiovascular disease
As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]
Bibcode:1992PNAS...89.8641T